STOCK TITAN

PaxMedica, Inc. - PXMD STOCK NEWS

Welcome to our dedicated page for PaxMedica news (Ticker: PXMD), a resource for investors and traders seeking the latest updates and insights on PaxMedica stock.

PaxMedica, Inc. (PXMD) is a clinical-stage biopharmaceutical company pioneering anti-purinergic therapies for neurological disorders and neglected tropical diseases. This page provides investors and healthcare stakeholders with essential updates on clinical trial progress, regulatory developments, and therapeutic innovations.

Access consolidated information on PaxMedica's investigational programs, including its intravenous suramin formulation targeting Autism Spectrum Disorder (ASD) and Human African Trypanosomiasis (HAT). Track critical milestones such as FDA submissions, manufacturing advancements, and responses to global health emergencies.

Key updates include clinical trial results, partnership announcements, intellectual property developments, and analyses of therapeutic mechanisms. This resource eliminates fragmented research by providing verified information directly from company releases and trusted third-party coverage.

Bookmark this page for streamlined monitoring of PaxMedica's progress in developing treatments for complex neurological conditions and tropical diseases. Check regularly for authoritative updates reflecting the company's commitment to addressing unmet medical needs through rigorous scientific research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.63%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
-
Rhea-AI Summary

PaxMedica, Inc. (Nasdaq: PXMD) reported significant developments in its business update for Q4 2022 and the year ended December 31, 2022. The company initiated a Phase 3 clinical program for PAX-101, aiming for FDA submission. Key appointments were made, including Stefan Schwabe as Chief Medical Officer and Charles J. Casamento to the Board. They secured a $20 million equity investment agreement and an additional $2.5 million in growth capital. The pivotal Phase 3 HAT-301 trial results for treating Stage 1 TBR HAT are anticipated in the second half of 2023, with plans for an IND submission for PAX-101 targeting ASD in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
-
Rhea-AI Summary

PaxMedica, Inc. (Nasdaq: PXMD) held a Scientific Advisory Board meeting from March 10-12, 2023, adding several leading experts in autism spectrum disorder (ASD) to its board. These experts include Dr. Robert Naviaux and Dr. Robert Findling, among others. The purpose of the meeting was to advance the development of suramin, a potential treatment for core symptoms of ASD. The company anticipates launching international multicenter clinical trials for suramin in 2024. PaxMedica focuses on anti-purinergic drug therapies for neurologic disorders, including ASD and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
management
Rhea-AI Summary

PaxMedica, Inc. (Nasdaq: PXMD) has announced significant progress in its 2022 shareholder letter, outlining key milestones achieved and anticipated over the next 12-24 months. The company aims to initiate clinical trials for PAX-101 (suramin) targeting Autism Spectrum Disorder (ASD) in the U.S. Following its IPO in August 2022, PaxMedica raised $6.8 million and secured an equity investment agreement potentially worth $20 million from Lincoln Park Capital. They initiated a Phase 3 trial for HAT-301 in November, focusing on Human African Trypanosomiasis (HATr). Successful trial results could lead to expedited NDA approval and revenue through a Priority Review Voucher.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.64%
Tags
none
-
Rhea-AI Summary

PaxMedica, Inc. (Nasdaq: PXMD) has secured a funding agreement providing net proceeds of $3.2 million through a $3.68 million convertible note from Lind Global Partners II, LP. The note features an 0% interest rate and a conversion price of $3.50 per share, with repayments due in 12 monthly installments starting 180 days after funding. The CEO, Howard Weisman, expressed optimism that this capital will aid in developing PAX-101 for autism spectrum disorder (ASD). Additionally, Lind will receive a four-year warrant for 800,000 shares at $3.25 each. More details will be in a forthcoming SEC filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
none
-
Rhea-AI Summary

PaxMedica, Inc. (Nasdaq: PXMD) announced its participation in the Virtual Investor Summit on January 26, 2023, at 1:30 PM EST. The summit will feature 25 micro-cap companies with strong market performance, allowing qualified investors to engage in one-on-one sessions. PaxMedica focuses on developing anti-purinergic drug therapies for neurologic disorders, including Autism Spectrum Disorder and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. The company aims to advance its lead program, PAX-101, an intravenous formulation of suramin, targeting ASD and exploring its potential against Long COVID-19 Syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.73%
Tags
none
PaxMedica, Inc.

Nasdaq:PXMD

PXMD Rankings

PXMD Stock Data

2.76M
125.63M
0.78%
0.15%
8.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
TARRYTOWN